- Trial phase
- Approved
- Time to market
- Already approved and commercially launched as of August 19, 2026.
- Why 4/10
- Pasatru was FDA-approved on August 19, 2026, so the defining binary catalyst has passed. No new PDUFA or pivotal readout is scheduled in the next ~12 months; the planned OPTIMA 2 pediatric Phase 3 trial start is not a hard binary catalyst. As a small part of Regeneron's large pipeline (~$89B market cap, $4.3B quarterly revenue), Pasatru alone cannot drive a major share-price move, so impactScore is 4.
Pasatru is already approved and launching commercially; the next catalyst is the start of the Phase 3 OPTIMA 2 pediatric/adolescent trial (planned for later 2026), which would expand the addressable population but is not a binary event. Watch Q3 2026 earnings (today, Oct 30) for initial Pasatru sales commentary and any updates on OPTIMA 2 enrollment timing. For a company with ~$89B market cap and $4.3B quarterly revenue, Pasatru is a small but strategically important rare-disease franchise builder.
Price Chart
Executive Summary
Pasatru (garetosmab-grts) is Regeneron's FDA-approved monoclonal antibody for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder affecting roughly 900 US patients. Approved on August 19, 2026 via Priority Review, it is the first and only treatment that reduces both new abnormal bone formation and flare-ups in adults with FOP. The Phase 3 OPTIMA trial showed a 90%+ reduction in new bone lesions at 56 weeks, and 84-week extension data (presented October 2026 at ASBMR and published in The Lancet) showed zero new lesions from week 56 to 84. Annual list pricing ranges from $693,000 to $2.1 million depending on dose and patient weight. For Regeneron, a large-cap biotech with ~$89B market cap and blockbuster products like Eylea and Dupixent, Pasatru represents a small but strategically important entry into rare disease, though it is unlikely to materially move the stock on its own.
How It Works
Pasatru is a lab-made antibody (a type of protein) that blocks a signaling molecule called activin A. In people with FOP (sometimes called 'stone man disease'), a genetic mutation causes activin A to trigger bone growth in muscles, tendons and ligaments where bone should not form. By neutralizing activin A, Pasatru prevents this abnormal bone formation and reduces painful flare-ups. It is given as a one-hour intravenous infusion once every four weeks.
Trial Status
The Phase 3 OPTIMA trial (56-week placebo-controlled + 84-week open-label extension) in adults with FOP is complete with positive results published in The Lancet. A separate Phase 3 trial in pediatric/adolescent patients (OPTIMA 2) is planned to begin later in 2026 but has not yet started recruiting.
The Two-Sided Case
Upcoming Catalysts
- OPTIMA 2 Phase 3 trial initiation in pediatric/adolescent FOP patients (planned later 2026)
- Initial Pasatru sales commentary on Regeneron Q3 2026 earnings call (October 30, 2026)
- Potential European Medicines Agency (EMA) filing for EU approval
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Regeneron Pharmaceuticals, Inc. PRESS-RELEASE REGN ·Originating report